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Abstract
Introduction Cardiovascular failure is the leading cause of
death in severe acute drug intoxication. In this setting, we report
the feasibility, complications, and outcome of emergency
extracorporeal life support (ECLS) in refractory shock or cardiac
arrest following a drug overdose.
Methods This is a retrospective cohort study of 17 patients
admitted over a 10-year period for prolonged cardiac arrest or
refractory shock following a drug overdose and not responding
to optimal conventional treatment. Patients were evaluated in
the medical ICU and cardiovascular surgery department of a
university hospital. ECLS implantation used a centrifugal pump
connected to a hollow-fiber membrane oxygenator and was
performed in the operating room (n = 13), intensive care unit (n
= 3), or emergency department (n = 1). ECLS was employed for
refractory shock and prolonged cardiac arrest in 10 and 7
cases, respectively.
Results The mean duration of external cardiac massage was
101 ± 55 minutes. Fifteen patients had ingested cardiotoxic
drugs, including 11 cases of drugs with membrane stabilizing
activity. Time from hospital admission to initiation of ECLS was
6.4 ± 7.0 hours. Time to ECLS implant was 58 ± 11 minutes.
The mean ECLS flow rate was 3.45 ± 0.45 L/min. The average
ECLS duration was 4.5 ± 2.4 days. Early complications
included limb ischemia (n = 6), femoral thrombus (n = 1), cava
inferior thrombus (n = 1), and severe bleeding at the site of
cannulation (n = 2). Fifteen patients were weaned off ECLS
support and 13 (76%) were discharged to hospital without
sequelae.
Conclusions Based on our experience, we consider ECLS as a
last resort, efficient, and relatively safe therapeutic option in this
population. However, the uncontrolled nature of our data
requires careful interpretation.
Introduction
Drug-induced cardiovascular failure is the leading cause of
death in severe acute drug intoxication [1,2]. In this setting,
patients with refractory shock or cardiac arrest who do not
respond to optimal conventional treatment may need special
therapies, such as extracorporeal life support (ECLS).
Although cardiovascular bypass is rarely used in the manage-
ment of poisoning, it may have potential benefits for hemody-
namic instability not responding to conventional measures.
Promising results have been obtained using temporary circu-
latory support in several single-case reports [3-17] and short
series [18,19]. However, the usefulness of cardiovascular
bypass in drug-induced cardiac failure remains unclear [20].
The aim of the study was to describe our 10-year experience
of ECLS as a last resort therapeutic option in acute poisoning.
Seven of the cases included in this series were previously pub-
lished [15,18].
Materials and methods
We reviewed the cases of all patients treated with emergency
cardiopulmonary bypass for prolonged cardiac arrest or car-
diogenic shock following drug intoxication at the University
Hospital of Caen between 1997 and 2007. Our medical
teams and nurses have a large amount of experience with
ACT: activated clotting time; CPC: cerebral performance class; ECLS: extra corporeal life support; MSA: membrane stabilizing activity; SAPS: Sim-
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emergency ECLS, specifically among critically ill patients
[15,18,21,22].
Patients
During the study period, 721 patients were admitted for drug
intoxication (Figure 1). One hundred and ten patients had
hemodynamic failure responding to conventional treatment
and 17 patients had refractory shock or cardiac arrest. In our
practice, patients with refractory cardiac arrest, defined as an
absence of return to spontaneous circulation after continuous
cardio-pulmonary resuscitation over at least 45 minutes or
refractory shock, defined as shock not responding to optimal
conventional treatment, were candidates for ECLS support
[23]. When the decision to implant ECLS was made by a sen-
ior intensivist, a senior cardiac surgeon and a perfusionist
were immediately informed and ECLS performed.
Data collection
According to French legislation at the time of the study and
given the observational retrospective nature of the study, no
ethical committee was requested and thus no informed con-
sent was obtained from the patients. At the time of ECLS
implantation the focus was specifically on hemodynamic
(including electrocardiographic and echocardiographic), neu-
rologic, respiratory, renal, liver, and hematologic data. Meas-
ured physiological variables were used to calculate the
Simplified Acute Physiology Score (SAPS II) [24] and the
Sequential Organ Failure Assessment (SOFA) score [25]. The
toxicological screening was recorded and drugs classified as
with or without cardiotoxic effect or membrane stabilizing
activity (MSA). In addition, the clinical course of each patient
during hospitalization was recorded. Vascular, neurologic,
hemorrhagic, renal, and perfusion system complications were
documented. The neurologic outcome at hospital discharge
was assessed according to the cerebral performance class
(CPC) categories [26]: CPC 1 = good cerebral performance,
CPC 2 = moderate cerebral disability, CPC 3 = severe cere-
bral disability, CPC 4 = coma or vegetative state, and CPC 5
= brain death or death.
Cannulation technique
Device description, cannulation technique, management, and
weaning from ECLS were previously reported in detail [22].
Briefly, the hardware for cardiopulmonary circulation con-
sisted of a Biomedicus portable system (Medtronic, Inc, Min-
neapolis, MN, USA) incorporating a centrifugal pump console
and a water pump system. The closed ECLS circuit consisted
of pre-connected polyvinyl chloride tubing (Medtronic, Inc,
Minneapolis, MN, USA) including a constrained vortex pump
chamber, a hollow-fiber membrane oxygenator with an integral
heat exchanger (Maxima PRF, Medtronic, Inc, Minneapolis,
MN, USA), and a flow probe. All components were heparin-
coated (Carmeda Bioactive Surface-coating). The cannulae
were Biomedicus (17 F to 25 F), according to the size of
patients.
Once the decision to implant ECLS support was made, the cir-
cuit was quickly primed with normal saline. Heparin was
administered to the patient at 50 UI/kg immediately before
cannulation of the vessels. The activated clotting time (ACT)
was kept between 150 and 200 seconds at full-flow assist-
ance. Peripheral femorofemoral cannulation was surgically set
up using a modified Seldinger technique. Because cannula-
tion-related limb ischemia was a major problem when we
began this technique, additional distal limb perfusion was
inserted to avoid severe leg ischemia. The distal tip of the arte-
rial cannula was positioned in the common iliac artery or distal
abdominal aorta, whereas the tip of the venous cannula was
set in the right atrium under echocardiographic guidance and
confirmed by chest radiograph.
Patient management during ECLS
Pump flow was initially set at 2.5 L/m2 and vasopressor (nore-
pinephrine and epinephrine) was used to maintain a mean
blood pressure of at least 60 mmHg. An inotropic support was
used even if systemic perfusion was adequately performed by
ECLS to maintain a pulsatile flow through the native heart. The
aim was to decompress the left heart and minimize stasis,
therefore reducing the risk of intracardiac thrombosis. If nec-
essary, to accomplish mechanical decompression of the left
heart, an atrial balloon septostomy was performed. A femoral
vein approach was used in which a transeptal puncture, fol-
lowed by blade septostomy, was performed under combined
radioscopy and echocardiographic guidance. Sequential bal-
loon inflations were carried out to achieve left heart decom-
pression, which was confirmed by echocardiography. The
ECLS was monitored by trained ICU personnel. A perfusionist
was also available for occasional monitoring visits and emer-
Figure 1
Flow chart indicating patient characteristics Flow chart indicating patient characteristics. CPC: cerebral perform-
ance class; ECLS: extra corporeal life support; ICU: intensive care unit.Available online http://ccforum.com/content/13/4/R138
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gencies. Echocardiography was used serially to assess pro-
gressive myocardial recovery and exclude intracardiac
thrombosis or other abnormalities. All patients were mechani-
cally ventilated with 5 to 6 mL/kg tidal volume and 8 to 10
cmH2O positive end-expiratory pressure, and continuous ven-
ovenous hemofiltration was used to treat acute renal failure
and regulate the intravascular volume and overall fluid balance,
if necessary.
Weaning
The decision to discontinue ECLS support was based on evi-
dence of multiorgan failure, overwhelming sepsis, or severe
neurological injury. Patients were weaned off ECLS if the left
ventricular ejection fraction, assessed by echocardiography
during a reduction of pump flow to 500 to 1000 mL/min, was
stable (> 50%) without deterioration in hemodynamic status.
During this period, anticoagulation was adapted to adequate
values of ACT (250 to 300 seconds). If the patient's cardio-
vascular status remained stable, ECLS was withdrawn by car-
diac surgeons.
Statistical analysis
Quantitative and qualitative data are expressed as mean (±




Seventeen patients (11 females, 6 males; mean age 39 ± 18
years) were treated with ECLS following drug intoxication. All
patients, except two, had ingested cardiotoxic drugs, including
11 cases of drugs with MSA. The majority (12/17) of poison-
ings resulted from mixed poisonings involving a combination of
cardiotoxic drugs, various psychotic drugs, and alcohol (Table
1).
Baseline characteristics
The baseline characteristics of patients at the time of ECLS
implantation are reported in Table 2. All patients, except two,
were comatose. The patients' median SAPS II score was 69
(26 to 82) and median SOFA score was 13.5 (3 to 18). The
ECLS setup was performed for 13 patients in the operating
room, 3 in the intensive care unit, and 1 in the emergency
department. Seven patients received ECLS during external
cardiac massage for refractory cardiac arrest, which occurred
in six cases at hospital admissions in the emergency room. Ten
other patients also received ECLS, including two after the res-
toration of spontaneous circulation following a brief period of
asystole, during refractory shock. The mean duration of exter-
nal cardiac massage was 101 ± 55 minutes.
Table 1
Patients and drugs used
Patients Drugs
1 Sotalol 4.8 g, verapamil 7.2 g
2 Disopyramide* 10 g, alprazolam 10 mg
3 Acebutolol* 10 g, méprobamate 4 g, aspirin 15 g, alprazolam 10 mg
4 Tianeptine, Bromazepam, fluoxetine, zolpidem 4 g
5 Verapamil 1.2 g, propanolol* 4 g, betaxolol 6.8 g
6 Acebutolol* 8 g, meprobamate 5 g
7 Flecaine*8 g, venlafaxine
8 Verapamil
9 Disopyramide* 3 g, lithium 7.5 g, citalopram 0.2 g
10 Propanolol* 2 g, meprobamate, paroxetine, paracetamol, dextropropoxyfene
11 Metoprolol, alcohol
12 Verapamil 3.6 g
13 Propanolol* 2 g, alcohol
14 Cibenzoline*, benzodiazepines
15 Tramadol 10 g, hydroxyzine 6 g, gabapertine 1 g, clonazepam 80 mg
16 Propafénone*, alcohol, oxilamine
17 Propanolol*
* Drugs with membrane stabilizing activity (MSA).Critical Care    Vol 13 No 4    Daubin et al.
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Before the initiation of ECLS support, a severe decrease in
cardiac contractility was documented by echocardiography in
14 cases. All patients were mechanically ventilated and
received vasopressor. Four patients needed temporary exter-
nal transthoracic electrostimulation. Six patients required con-
tinuous venovenous hemofiltration or conventional dialysis for
acute renal failure before or immediately after ECLS implanta-
tion. Before connection to ECLS, the median arterial pH was
7.37 (7.34 to 7.41), partial presure of arterial oxygen/fraction
of inspired oxygen ratio was 239 (180 to 261), serum bicarbo-
nate concentration was 19.0 mmol/L (17.7 to 20.6), plasma
lactate concentration was 5.9 mmol/L (3.7 to 9.7), and serum
creatinine concentration was 160 μmol/L (114 to 204).
ECLS feasibility
ECLS feasibility, assessed with respect to time from admis-
sion to ECLS initiation, and the percentage of successful pro-
cedures (i.e. flow rate > 2.5 L/m2 and mean blood pressure >
60 mmHg) is shown in Table 3. Time from hospital admission
to initiation of ECLS was 6.4 ± 7.0 hours, and the time to
ECLS implant was 58 ± 11 minutes. The mean ECLS flow rate
was 3.45 ± 0.45 L/min. The average ECLS duration was 4.5
Table 2
Baseline characteristics at the time of ECLS implantation*




1§ 160 3 0 0 Epinephrine Asystole Akinesia - 21.1
2§¶ 150 3 0 0 Epinephrine Asystole - > 30 17.8
3§¶ 170 3 0 0 Epinephrine 
Isoproterenol
Asystole Akinesia 10.8 19





5 70 3 0 0 Epinephrine Asystole - 7.3 26.3
6 50 3 0 0 - Asystole Akinesia - -






No 3 60 50/30 Epinephrine 
Isoproterenol
Sinusal - 10.5 17.7
























13** No 3 55 75/50 Epinephrine Sinusal Hypokinesia 
(LVEF 30%)
5.9 11.7






















* For patients with cardiac arrest, we provided data recorded just before cardiac arrest if available
** ECLS performed after restoration of spontaneous circulation following a brief period of asystole
§ Patients with temporary external transthoracic electrostimulation before initiation of ECLS
¶ Patients requiring continuous venovenous hemofiltration or conventional dialysis before or immediately following ECLS implantation
AP: arterial pressure; ECG: echocardiogram; ECM: manual external cardiac massage; ECLS: extra corporeal life support; HR: heart rate; GCS: 
Glasgow coma score; LVEF: left ventricular ejection fraction; QRS: duration of the complex representing ventricular depolarization on 
electrocardiogram.Available online http://ccforum.com/content/13/4/R138
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± 2.4 days. In one patient (no. 17), an atrial balloon septo-
stomy was performed to accomplish mechanical decompres-
sion of the left heart.
ECLS complications
Significant cannulation-related injuries of femoral vessels were
reported in 10 patients: six patients with limb ischemia requir-
ing urgent revascularization in three cases, one femoral throm-
bus, one cava inferior thrombus, and two cases of severe
bleeding at the site of cannulation requiring a surgical revision.
Clinical outcome
Fifteen patients were weaned off ECLS support and two
patients withdrawn from support because of refractory multior-
gan failure and cerebral death (Table 3). Thirteen patients sur-
vived and were discharged to hospital without significant
cardiovascular or neurological sequelae (CPC 1 n = 9 and
CPC 2 n = 4). Two patients died of septic shock and cerebral
death during the hospital stay.
Discussion
We report one of the largest series of drug-induced cardiac
arrest and refractory shock managed with ECLS. The high sur-
vival rate (76%) reported in this setting supports ECLS as an
efficient rescue treatment in a subset of patients with drug-
induced circulatory failure not responding to optimal conven-
tional treatment.
Patients and drugs
Clinical experience with emergency ECLS during poisoning
leading to prolonged cardiac arrest or shock that does not
respond to conventional treatment is limited [3-19]. Poly-intox-
ication including cardiotoxic drugs with MSA, which is known
to be associated with a high mortality rate [27], was involved
in a majority of cases, as previously reported [28]. All patients
were in prolonged cardiac arrest or refractory shock according
to the definitions proposed by Baud and colleagues [28].
ECLS feasibility and efficiency
We confirmed the feasibility of emergency ECLS in accord-
ance with previous reports focusing on prolonged cardiac
arrest regardless of the cause [19,22]. The physiologic objec-
tive was to provide temporal circulatory support to the vital
organs and unload the failing heart as the injured myocardium
attempts to recover. In previous cohort studies [19,22], sur-
vival rates were clearly higher in the toxic cardiac arrest group,
Table 3
ECLS feasibility, duration and complications




Time to implant 
ECLS* (min)




LVEF at ECLS 
discharge
Long term surviving
1** 2.5 60 3.5 2 - No
2** 1.5 60 3 3 - No
3 2 hours 50 mins 40 3.5 2.3 62% Yes
4 1 60 3.5 2.5 > 50% Yes
5 1 60 - 2.5 76% Yes
6 16 0 3 . 5 2 . 3-Y e s
7 66 0 3 . 63 5 6 % Y e s
8 56 0 3 . 7 1 1-N o
9 66 0 3 . 45 n o r m a l N o
10 24 60 4 5 42% Yes
11 46 0- 4 3 8 % Y e s
12 26 04 6 >  5 0 % Y e s
13 2.5 45 2.6 7 74% Yes
14 15 90 4 6 45% Yes
15 16 60 2.5 8 45% Yes
16 36 0 3 . 54 5 0 % Y e s
17 17 40 3.5 3 40% Yes
* Delay between ECLS decision and time at which ECLS flow was provided
** Patients dead during ECLS assistance
ECLS: extra corporeal life support; LVEF: left ventricular ejection fraction.Critical Care    Vol 13 No 4    Daubin et al.
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as compared with other causes of cardiac arrest (3 of 12 vs 0
of 5 [19] and 4 of 6 vs 4 of 34 [22], respectively). The high sur-
vival rate (76%) reported in our cohort was in accordance with
the general survival rate from 58% (15 of 26) in case reports
of poisoned patients who benefited from ECLS [3-
14,16,17,19]. The 5 of 7 (71%) survival rate we reported
among patients with cardiac arrest was in contrast with the
dramatically low survival rate of 7% and 4.5%, respectively,
reported in overdoses involving cardiac arrest [29,30]. To our
knowledge, no studies have reported the survival rate of
patients with drug-induced cardiovascular shock apparently
refractory to conventional treatment, limiting comparisons with
our cohort. However, experimental studies with control groups
demonstrated that ECLS improved survival in animal models of
severe cardiotoxic drug-induced shock [31,32]. These results
suggest that ECLS could be considered as a good emergency
resuscitative tool in this setting.
ECLS complications
Severe cannulation-related limb ischemia was the major prob-
lem when we first started the technique. Therefore, to accom-
plish a perfusion of the distal limb, surgeries performed an
additional arterial shunt with a small 8 F catheter between the
side port of arterial cannula and a point located some centim-
eters distally in the superficial femoral artery shunt. After this
supplementary shunt was added, only distal embolic ischemia
were reported. In contrast to Mégarbane and colleagues [19],
the rate of cannulation-related complications, limb ischemia,
and major bleeding was relatively high despite the modified
Seldinger technique and additional distal limb perfusion.
These differences could be explained by a higher ECLS dura-
tion in our study. However, our results were in accordance
with reports of significant morbidity associated with emer-
gency ECLS [33]. In addition, no death was induced by can-
nulation-related complications, and all survivors were
discharged without significant cardiovascular or neurological
sequelae.
Limitations
Firstly, because ECLS indication for drug overdose is rare, the
sample size is small. Secondly, the uncontrolled retrospective
observational design does not permit clarification of the role of
ECLS therapy in drug-induced cardiac failure in a therapeutic
algorithm. However, because usefulness of ECLS in this set-
ting remains debatable [20], we believe this study adds impor-
tant information about ECLS as a rescue therapy in patients
with drug-induced cardiac arrest and refractory shock.
Conclusions
Based on our experience, we consider ECLS as a last resort,
efficient, and relatively safe therapeutic option in critically ill
poisoned patients (i.e. cardiac arrest and refractory shock)
who do not respond to conventional therapies, providing the
cardiac surgeon with the means to rapidly intervene and con-
trol ECLS-related complications. However, because there is
insufficient evidence concerning the use of ECLS as a treat-
ment for severe cardiac impairment due to poisoning, further
studies are needed to clarify criteria for unresponsiveness to
conventional treatment and the indications of ECLS in this set-
ting.
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